Cardiac safety of fingolimod 0.5 mg during the first-dose observation in a 4-month, open-label, multicentre FIRST study in relapsing multiple sclerosis patients

Cardiac safety of fingolimod 0.5 mg during the first-dose observation in a 4-month, open-label, multicentre FIRST study in relapsing multiple sclerosis patients

Détails bibliographiques
Auteurs principaux: Gold, R, Kappos, L, Palace, J, Siever, A, Marrosu, M, Gottschalk, R, Bijarnia, M, Keil, A, Tomic, D, von Rosenstiel, P, Comi, G
Format: Conference item
Publié: 2012

Documents similaires